Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

New anticoagulants for the prevention of venous thromboembolism.

Becattini C, Lignani A, Agnelli G.

Drug Des Devel Ther. 2010 May 25;4:49-60. Review.

2.

The potential benefits of low-molecular-weight heparins in cancer patients.

Robert F.

J Hematol Oncol. 2010 Jan 14;3:3. doi: 10.1186/1756-8722-3-3. Review.

3.

Thrombotic complications following liver resection for colorectal metastases are preventable.

Morris-Stiff G, White A, Gomez D, Toogood G, Lodge JP, Prasad KR.

HPB (Oxford). 2008;10(5):311-4. doi: 10.1080/13651820802074431.

4.

Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review.

Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Sch√ľnemann HJ.

J Exp Clin Cancer Res. 2008 Jul 18;27:21. doi: 10.1186/1756-9966-27-21. Review.

5.

Venous thromboembolism in the outpatient setting.

Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ.

Arch Intern Med. 2007 Jul 23;167(14):1471-5.

6.

Venous thromboembolic disease and cancer.

Fennerty A.

Postgrad Med J. 2006 Oct;82(972):642-8. Review.

7.

A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.

Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G.

Ann Surg. 2006 Jan;243(1):89-95.

8.

The hypercoagulable state of malignancy: pathogenesis and current debate.

Caine GJ, Stonelake PS, Lip GY, Kehoe ST.

Neoplasia. 2002 Nov-Dec;4(6):465-73. Review.

9.

Antithrombotic therapy in cancer.

Kakkar AK, Williamson RC.

BMJ. 1999 Jun 12;318(7198):1571-2. No abstract available.

Supplemental Content

Support Center